CancerNetwork®

🎥 Our most recent youtube video features breaking data from IBC East and conversations with leading breast cancer oncologists 🎥 Check it out here: hubs.li/Q03y20Ky0 #bcsm | @gotoPER

Patients with nonmetastatic esophageal cancer who received FLOT chemotherapy achieved a 3-year OS rate of 61.1% in an analysis of the phase 3 ESOPEC trial. #esocsm hubs.li/Q03yn01x0

New research suggests high levels of CD163-positive tumor-associated macrophages may significantly improve nivolumab efficacy in metastatic RCC. #KCRS2025 #kcsm hubs.li/Q03ymYGF0

Adding post-transplant cyclophosphamide-based GVHD prophylaxis following allogenic HSCT resulted in favorable 1-year OS outcomes in patients undergoing HSCT with HLA-mismatched unrelated donors. #oncology hubs.li/Q03ymZSG0

Osimertinib combined with platinum-containing chemotherapy as frontline treatment improved overall survival vs osimertinib alone among patients with locally advanced or metastatic NSCLC harboring EGFR mutations. #lcsm #NSCLC hubs.li/Q03ymXL50

Meet the panel: @AjaiChari, @AjayNookaMD, @MMBaljevicMD, @GKaurMD, and @anupamakumar05—watch as they explore how #Teclistamab and #Elranatamab compare in relapsed/refractory #MultipleMyeloma. In Episode 3 of Around the Practice, they break down efficacy, safety, and clinical…

Kiran Turaga, MD, MPH, was the research lead of an initiative to put together new clinical guidelines for the care of peritoneal surface malignancies. #oncology hubs.li/Q03ymY640

The FDA has issued a CRL to vusolimogene oderparepvec in combination with nivolumab for the treatment of patients with advanced melanoma who were previously administered an anti–PD-1 regimen. #melsm hubs.li/Q03ymHxz0

A novel CAR T-cell therapy option to target CAIX/CD70 overexpression has the potential to show promise in clear cell renal cell carcinoma. #kcsm #KCRS2025 hubs.li/Q03y7HYl0

Short-course radiotherapy combined with sintilimab plus oxaliplatin-capecitabine yielded a pCR rate of 59.2% vs 32.7% with the control arm in locally advanced rectal cancer. #crcsm hubs.li/Q03y7zFb0

Immune activation showed promise in early data on neoantigen vaccines, including durable antitumor activity for select patients with kidney cancer. #kcsm #KCRS2025 hubs.li/Q03y7vWz0

At the 2024 Kidney Cancer Research Summit, researchers from Dana-Farber presented data showing baseline radiologic tumor burden may predict survival in mccRCC, even before first-line IO therapy begins. Results showed that a 1 cm increase raised death risk by 5%. Could imaging…

There was no difference in breast cancer-related events in women who breastfed for 4 months or longer after a breast cancer diagnosis, according to follow-up results from the POSITIVE trial. #bcsm hubs.li/Q03y7zwb0

The confirmed ORR with mirdametinib was 41%, significantly higher than the predefined minimum clinically relevant response rate of 23% (P < .001). #oncology #pedcsm hubs.li/Q03y7tXm0

Following an 8-to-1 ODAC ruling against the applicability of the phase 3 STARGLO results in US patients, a CRL has been issued for glofitamab in relapsed/refractory DLBCL. #lymsm hubs.li/Q03y7fq90

With the recent approvals of T-DXd and Dato-DXd, the care for breast cancer continues to evolve and expand. #bcsm | @ErikaHamilton9 cancernetwork.com/view/dissectin…

Among all evaluable patients who received pembrolizumab/lenvatinib, the ORR was 50.6% (95% CI, 42.6%-58.7%), a DCR of 82.3% (95% CI, 75.4%-87.9%), and a CBR of 71.5% (95% CI, 63.8%-78.4%). #kicsm #KCRS2025 | @kidneycan @AlbigesL cancernetwork.com/view/pembroliz…

The FDA has granted fam-trastuzumab deruxtecan-nxki breakthrough therapy designation as a first-line treatment for adult patients with unresectable or metastatic HER2-positive breast cancer. #bcsm cancernetwork.com/view/t-dxd-gra…

Metastasis-directed RT without systemic therapy demonstrated promising efficacy, including favorable survival and toxicity, in the treatment of patients with oligometastatic clear cell renal cell carcinoma. #kicsm #KCRS2025 | @kidneycan @ChadTangMD cancernetwork.com/view/metastasi…

The relative gain in Q-TWiST with belzutifan, defined as the absolute Q-TWiST difference divided by mean OS for the everolimus arm, was 11.32% (range, 4.49%-19.09%) in the main analysis. #kicsm #KCRS2025 | @tompowles1 @kidneycan cancernetwork.com/view/belzutifa…